Pharmacokinetics of Niacin, Simvastatin and their Metabolites in Healthy Chinese Subjects after Single and Multiple Doses of a Fixed Dose Combination Tablet of Niacin Extended Release/Simvastatin

M. Liu; X. L. Wang; D. Zhang; M. Yang; J. Han; Y. N. Zhang; Z. L. Wang; H. C. Liu

doi:10.1055/s-0033-1357190

Drug Research, Table of Contents

Drug Res (Stuttg) 2014; 64(6): 296-300
DOI: 10.1055/s-0033-1357190

Original Article

Pharmacokinetics of Niacin, Simvastatin and their Metabolites in Healthy Chinese Subjects after Single and Multiple Doses of a Fixed Dose Combination Tablet of Niacin Extended Release/Simvastatin

Authors

M. Liu

¹Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, P. R. China
X. L. Wang

¹Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, P. R. China
D. Zhang

¹Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, P. R. China
M. Yang

¹Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, P. R. China
J. Han

¹Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, P. R. China
Y. N. Zhang

¹Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, P. R. China
Z. L. Wang

¹Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, P. R. China
H. C. Liu

¹Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, P. R. China

Abstract

Objective: A fixed dose combination tablet of niacin extended release (ER)/simvastatin was recently developed in China. This study was designed to assess and compare the pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses administration.

Methods: From day 1 to day 7, 12 Chinese subjects were given a tablet every day at approximately 10 p.m. Serial blood samples were collected. Niacin and nicotinuric acid (NUA) in plasma, niacin, NUA, N-methylnicotinamide (MNA) and N-methyl-2-pyridone-5-carboxamide (2PY) in urine, simvastatin and simvastatin acid in plasma were determined by LC/MS/MS methods. Pharmacokinetic parameters on days 1 and 7 were compared.

Results:The main pharmacokinetic parameters for the single and multiple doses were as follows: Niacin: T_max were 3.8±1.5 h and 3.9±2.0 h; C_max were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC_0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml. NUA: T_max were 4.7±1.7 h and 3.8±1.5 h; C_max were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC_0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml. Simvastatin: T_max were 1.8±1.0 h and 2.5±2.5 h; C_max were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC_0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml. Simvastatin acid: T_max were 5.8±1.7 h and 6.5±1.4 h; C_max were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC_0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml. Urine Recovery rate of total niacin: (40.55±7.38)% and (62.87±12.04)%.

Conclusion: Compared with those after a single dose, pharmacokinetics of niacin and NUA was similar; total urine recovery of niacin was higher; exposure to simvastatin and simvastatin acid were higher following multiple doses.

Key words

niacin - nicotinuric acid - simvastatin - simvastatin acid - pharmacokinetics

Full Text

References

References
1 Hess DC, Fagan S. Pharmacology and clinical experience with simvastatin. Exp Opin Pharmacother 2001; 2: 153-163
2 Abbott Simcor: clinical pharmacology and biopharmaceutics review(s) [Online] Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails Accessed on 9 April 2012
3 Mccormack PL, Keating GM. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 2005; 65: 2719-2740
4 Abbott Simcor: prescribing information [online] Available at: http://www.fda.gov/cder/foi/label/2008/022078lbl Accessed on 9 Sep 2008
5 Mullangi R, Srinivas NR. Niacin and its metabolites: role of LC-MS/MS bioanalytical methods and update on clinical pharmacology. An overview. Biomed Chromatogr 2011; 25: 218-237
6 Felsted R, Chaykin S. N-Methylnicotinamide oxidation in a number of mammals. J Biol Chem 1967; 242: 1274-1279
7 Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 2000; 86: 35L-40L
8 Keskitalo JE, Kurkinen KJ, Neuvonen PJ et al. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008; 84: 457-461
9 Szafarz M, Lomnicka M, Sternak M et al. Simultaneous determination of nicotinic acid and its four metabolites in rat plasma using high performance liquid chromatography with tandem mass spectrometric detection (LC/MS/MS). J Chromatogr B 2010; 878: 895-902
10 Apostolou C, Kousoulos C, Dotsikas Y et al. An improved and fully validated LC-MS/MS method for the simultaneous quantification of simvastatin and simvastatin acid in human plasma. J Pharm Biomed Anal 2008; 46: 771-779
11 Patel BN, Sharma N, Sanyal M et al. Simultaneous determination of simvastatin and simvastatin acid in human plasma by LC-MS/MS without polarity switch: Application to a bioequivalence study. J Sep Sci 2008; 31: 301-313
12 Menon R, Tolbert D, Cefali E. The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet. Biopharm Drug Dispos 2007; 28: 297-306
13 Jang SB, Lee YJ, Lim LA et al. Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. Clinical Therapeutics 2010; 32: 206-216